VIVUS (STU:VIU1) Days Payable : 184.40 (As of Mar. 2020)

View and export this data going back to . Start your Free Trial

What is VIVUS Days Payable?

VIVUS's average Accounts Payable for the three months ended in Mar. 2020 was €8.46 Mil. VIVUS's Cost of Goods Sold for the three months ended in Mar. 2020 was €4.19 Mil. Hence, VIVUS's Days Payable for the three months ended in Mar. 2020 was 184.40.

The historical rank and industry rank for VIVUS's Days Payable or its related term are showing as below:

STU:VIU1's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 147.29
* Ranked among companies with meaningful Days Payable only.

VIVUS's Days Payable increased from Mar. 2019 (132.15) to Mar. 2020 (184.40). It may suggest that VIVUS delayed paying its suppliers.

VIVUS Days Payable Historical Data

The historical data trend for VIVUS's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VIVUS Days Payable Chart

VIVUS Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Days Payable

Get a 7-Day Free Trial

86.95

213.27

168.35

232.36

191.44

VIVUS Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
Days Payable	Get a 7-Day Free Trial															132.15	77.30	149.17	160.19	184.40

Competitive Comparison of VIVUS's Days Payable

For the Biotechnology subindustry, VIVUS's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

VIVUS's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VIVUS's Days Payable distribution charts can be found below:

* The bar in red indicates where VIVUS's Days Payable falls into.

VIVUS Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

VIVUS's Days Payable for the fiscal year that ended in Dec. 2019 is calculated as

	Days Payable (A: Dec. 2019 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2018 )	+	Accounts Payable (A: Dec. 2019 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2019 )	*	Days in Period
=	( (7.842	+	6.953)	/	2 )	/	14.104	*	365
=	7.3975					/	14.104	*	365
=	191.44

VIVUS's Days Payable for the quarter that ended in Mar. 2020 is calculated as:

	Days Payable (Q: Mar. 2020 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2019 )	+	Accounts Payable (Q: Mar. 2020 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2020 )	*	Days in Period
=	( (6.953	+	9.969)	/	2 )	/	4.187	*	365 / 4
=	8.461					/	4.187	*	365 / 4
=	184.40

VIVUS Days Payable Related Terms

Thank you for viewing the detailed overview of VIVUS's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

VIVUS (STU:VIU1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VIVUS Inc (STU:VIU1) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

900 East Hamilton Avenue, Suite 550, Campbell, CA, USA, 95008

Website

http://www.vivus.com

VIVUS Inc is a US-based biopharmaceutical company engaged in developing and commercializing, next-generation therapies to address unmet medical needs in human health. Its commercial products include Qsymia, an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index; PANCREAZE which is a is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreatic glands, as well as other enzyme classes and STENDRA/SPEDRA, which is an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.

VIVUS (STU:VIU1) Headlines

No Headlines